Cytokines and visceral leishmaniasis: A comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 6, 2012, Pages 735-739

  Costa, Alinne Silva Andrade ^a   Costa, Graciomar Conceição ^a   de Aquino, Dorlene Maria Cardoso ^a   de Mendonça, Vitor Rosa Ramos ^b   Barral, Aldina ^b   Barral Netto, Manoel ^b   Caldas, Arlene de Jesus Mendes ^a  

^a FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Clinical forms; Cytokines; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BLOOD; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; PRESCHOOL CHILD; VISCERAL LEISHMANIASIS;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; LEISHMANIASIS, VISCERAL; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867030637     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762012000600005     Document Type: Article

References (37)

1. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 293-243.
2. Ansari NA, Saluja S, Salotra P 2006. Elevated levels of interferon-gamma, interleukin-10 and interleukin-6 during active disease in Indian kala-azar. Clin Immunol 119: 339-345.
3. Bacellar O, Carvalho E 2005. Imunopatogênese da leishmaniose visceral. Gaz Med Bahia 75: 24-34.
4. Barral-Netto M, Badaró R, Barral A, Almeida RP, Santos SB, Badaró F, Pedral-Sampaio D, Carvalho EM, Falcoff E, Falcoff R 1991. Tumor necrosis factor/cachectin in human visceral leishmaniasis. J Infect Dis 163: 853-857.
5. Belkaid Y, Von Stebut E, Mendez S, Lira R, Caler E, Bertholet S, Udey MC, Sacks D 2002. CD8+ T cells are required for primary immunity in C57BL/c mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
6. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmüller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Röcken M 2001. IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2: 1054-1060.
7. Caldas A, Favali C, Aquino D, Vinhas V, Van Weyenbergh J, Brodskyn C, Costa J, Barral-Netto M, Barral A 2005. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
8. Engwerda CR, Ato M, Stager S, Alexander CE, Stanley AC, Kaye PM 2004. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol 165: 2123-2133.
9. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, El-Hassan AM, Russo DM, Reed SG 1993. Interleukin-10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324-329.
10. Ghalib HW, Whittle JA, Kubi M, Hashim FA, El-Hassan AM, Grabstein KH, Trinchieri G, Reed SG 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 154: 4623-4629.
11. Goto H, Lindoso JA 2004. Immunity and immunesuppression in experimental visceral leishmaniasis. Braz J Med Biol Res 37: 615-623.
12. Goto H, Prianti MG 2009. Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 51: 241-246.
13. Hailu A, Van Baarle D, Knol GJ, Berhe N, Miedem F, Kager PA 2005. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182-191.
14. Hailu A, Van Der Poll T, Berhe N, Kager PA 2004. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71: 561-567.
15. + cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis. Mem Inst Oswaldo Cruz 95: 217-220.
16. Jerônimo SM, Duggal P, Braz RF, Cheng C, Monteiro GR, Nascimento ET, Martins DR, Karplus TM, Ximenes MF, Oliveira CC, Pinheiro VG, Pereira W, Peralta JM, Sousa J, Medeiros IM, Pearsoni RD, Burns TL, Pugh EW, Wilson ME 2004. An emerging peri-urban pattern of infection with Leishmania chagasi, the protozoan causing visceral leishmaniasis in Northeast Brazil. Scand J Infect Dis 36: 443-449.
17. Karp CL, El-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB, Sacks DL 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 91: 1644-1648.
18. Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH 2009. Increased levels of IL-10, IL-12 and IFN-γ in patients with visceral leishmaniasis. BJID 13: 44-46.
19. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, Secor WE 2006. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69: 353-358.
20. Liu L, Wang L, Zhao Y, Wang Y, Wang Z, Qiao Z 2006. Testosterone attenuates p38 MAPK pathway during Leishmania donovani infection of macrophages. Parasitol Res 99: 18-193.
21. Maia-Elkhoury ANS, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA 2008. Visceral leishmaniasis in Brazil: trends and challenges. Cad Saude Publica 24: 2941-2947.
22. Medeiros IM, Castelo A, Salomão R 1998. Presence of circulating levels of interferon-γ, interleukin-10 and tumor necrosis factor-α in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 40: 31-34.
23. Melby PC, Chandrasekar B, Zhao W, Coe JE 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166: 1912-1920.
24. Michalick MSM, Genaro O 2005. Leishmaniose visceral americana. In D Neves, AL Melo, PM Linardi, RWA Vitor, Parasitologia humana, 11th ed., Atheneu, São Paulo, p. 56-72.
25. Miralles GD, Stoeckle MY, McDermott DF, Finkelman FD, Murray HW 1994. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62: 1058-1063.
26. MS/SVS - Ministério da Saúde/Secretaria de Vigilância em Saúde 2006. Manual de vigilância e controle da leishmaniose visceral. Available from: portal.saude.gov.br/portal/arquivos/pdf/manual_leish_visceral2006.pdf.
27. MS/SVS - Ministério da Saúde/Secretaria de Vigilância em Saúde 2009. Guia de vigilância em saúde (leishmaniose visceral). [cited 2009 Nov 11]. Available from: portal.saude.gov.br/portal/arquivos/pdf/gve_7ed_web_atual_lv.pdf.
28. Murray HW, Miralles GD, Stoeckle MY, McDermott DF 1993. Role and effect of IL-2 in experimental visceral leishmaniasis. J Immunol 151: 929-938.
29. + (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
30. Nylen S, Sacks D 2007. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
31. Park AY, Hondowicz BD, Scott P 2000. IL-4 is required to maintain a Th1 response during Leishmania major infection. J Immunol 165: 896-902.
32. Peruhype-Magalhães V, Martins-Filho OA, Prataz A, Silva LA, Rabello A, Teixeira-Carvalho A, Figueiredo RM, Guimarães-Carvalho SF, Ferrari TCA, Correa-Oliveira R 2005. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol 62: 487-495.
33. Peruhype-Magalhães V, Martins-Filho OA, Prataz A, Silva LA, Rabello A, Teixeira-Carvalho A, Figueiredo RM, Guimarães-Carvalho SF, Ferrari TCA, Van Weyenbergh J, Correa-Oliveira R 2006. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146: 124-132.
34. Stetson BD, Mohrs M, Mattlet-Designe V, Teyton L, Locksley RM 2002. Rapid expansion and IL-4 expression by Leishmania-specific naïve help T cells in vivo. Immunity 17: 191-200.
35. Trinchieri G 2007. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 204: 239-243.
36. Tumang MCT, Keogh C, Moldawer LL 1994. Role and effect of TNF-α in experimental visceral leishmaniasis. J Immunol 153: 768-775.
37. WHO - World Health Organization 2009. Leishmaniasis: magnitude of the problem. [cited 2009 Dec 15]. Available from: who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html.